Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Yulia Slavina
Yulia Slavina

PDS Biotechnology publishes Phase 2 immunotherapy results and shifts focus to PDS0301 in mCRC

PDS Biotechnology publishes Phase 2 immunotherapy results and shifts focus to PDS0301 in mCRC
PDS Biotechnology updates pipeline strategy

PDS Biotechnology announced that results from a Phase 2 trial of its HPV16-targeted immunotherapy, PDS0101, combined with pembrolizumab, have been published in JAMA Oncology.

The company stated it will now prioritize development of PDS0301 in metastatic colorectal cancer (mCRC) and is seeking partnership opportunities for PDS0101.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

The great sell-off: Why companies are dumping Bitcoin
  • By Pavlo Kot
  • 5 hours ago
The great sell-off: Why companies are dumping Bitcoin
Editors' Picks
Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents
  • By Pavlo Kot
  • Yesterday
Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents
Editors' Picks
China’s crypto paradox: A booming market despite the ban?
  • By Alena Volkova
  • Yesterday
China’s crypto paradox: A booming market despite the ban?
Editors' Picks
All Editors' Top Picks

Latest PDS News

Third quarter results released by PDS Biotechnology
  • By Elena Nikulina
  • Yesterday
Third quarter results released by PDS Biotechnology
Companies
#PDS
PDS Biotechnology appoints three new pharma executives to board
  • By Ksenia Gerey
  • 20.10.2026
PDS Biotechnology appoints three new pharma executives to board
Companies
#PDS
PDS Biotechnology to unveil new PDS0301 clinical outcomes at upcoming expert event
  • By Yaroslav Dmytrenko
  • 06.10.2026
PDS Biotechnology to unveil new PDS0301 clinical outcomes at upcoming expert event
Companies
#PDS
All PDS News
  • Pavlo Kot
  • 5 hours ago
The great sell-off: Why companies are dumping Bitcoin
  • Pavlo Kot
  • Yesterday
Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents
  • Alena Volkova
  • Yesterday
China’s crypto paradox: A booming market despite the ban?
  • Mikhail Vnuchkov
  • 13.11.2026
Global Microsoft outage: What happened and how serious is it?
  • Dmytro Kharkov
  • 13.11.2026
Meme stocks vs. memecoins: Same viral frenzy, different endgames
  • Yulia Slavina
  • 5 min ago
Gold market cap ratio reframes Bitcoin growth, Muneeb Ali notes
  • Mykhailo Ihnatenko
  • 35 min ago
Market recovery may begin in January after year-end profit taking, Joao Wedson notes
  • Pavlo Kot
  • 1 hour ago
Jesse Cohen: Top five developments to watch in U.S. stock market this week
  • Daria Chernytska
  • 1 hour ago
Behavioral Finance: Victor Ricciardi co-edits book on investor behavior and psychology
  • Yulia Slavina
  • 1 hour ago
Quinten Francois: Bitcoin and Ethereum underperform S&P 500 over five years
Top News
  • Ashutosh Sureka
  • 16 min ago
India stocks recover $400B as global investors reduce AI exposure
India stocks recover $400B as global investors reduce AI exposure
  • Mélissa Bac
  • 1 hour ago
Nvidia’s post-Huang era begins under growing pressure from Washington
Nvidia’s post-Huang era begins under growing pressure from Washington
  • Ezequiel Gomes
  • 2 hours ago
AI infrastructure stocks lose $4.2T as debt and valuation fears grow
AI infrastructure stocks lose $4.2T as debt and valuation fears grow
  • Pavlo Kot
  • 5 hours ago
The great sell-off: Why companies are dumping Bitcoin
The great sell-off: Why companies are dumping Bitcoin
  • Jainam Mehta
  • 22 hours ago
Goldman Sachs forecasts 19% return for Asian stocks in 2027
Goldman Sachs forecasts 19% return for Asian stocks in 2027
Live News
  • Mykhailo Ihnatenko
  • Now
AMD stock faces profit-taking risk as AI momentum builds
  • Olga Shendetskaya
  • Now
Eurozone economy outperforms expectations, strengthening case for ECB rate hike
  • Anton Kharitonov
  • Now
EUR/USD remains under pressure as dollar strength threatens a drop to 1.1000
  • Mykhailo Ihnatenko
  • Now
Ethereum drops below $2,000: Can ETH recover amid $1.64 billion in crypto liquidations?
  • Pavlo Kot
  • Now
Indian authorities raid CoinDCX and Delta Exchange over suspicious crypto transactions
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers